Andexanet alfa versus prothrombin complex concentrate for direct anticoagulation reversal in intracranial hemorrhage: a comparative effectiveness study
Abstract Background While guidelines recommend andexanet alfa (AA) for reversing factor Xa (FXa) inhibitors, its high cost and thrombotic risk have led to off-label use of 4-factor prothrombin complex concentrate (4F-PCC), despite limited comparative data. This comparative effectiveness study evaluates AA vs. 4F-PCC for bleeding control in clinical practice. Methods We conducted a retrospective review of patients with acute intracranial hemorrhage who were on a factor Xa inhibitor and received 4F-PCC or AA. Demographics, clinical severity, hemorrhage volume, treatment timing, and discharge outcomes were compared. Primary outcomes were absolute and percent hemorrhage volume change, substantial hemorrhage growth (> 6 mL or >33%), and neurological deterioration (≥ 2-point GCS decrease or ≥4-point NIHSS increase). Data were analyzed using Wilcoxon Rank Sum, chi-squared tests, and Kaplan–Meier curves. Results Among 132 eligible patients, 43 received AA and 89 received 4F-PCC. Traumatic bleeds accounted for 64% of cases. Mean age was 78 years, and average baseline hemorrhage volume was 37 mL. Age, gender, race, and door-to-needle times did not differ between groups. AA patients had higher NIHSS (9 vs. 5, p = 0.003) and lower GCS (12 vs. 13, p = 0.03) scores on admission. Mean absolute and percent hemorrhage volume changes were similar; however, more patients on AA had substantial hemorrhage growth (43% vs. 22%, OR=2.65, p = 0.02). After adjustment for covariates, the association between AA and substantial hemorrhage expansion narrowly missed statistical significance (adjusted OR 2.29, P = 0.08). Neurological deterioration rates and thromboembolic complications were comparable. Conclusions AA was linked to a numerically higher risk of substantial intracranial hemorrhage growth than 4F-PCC, despite similar rates of neurological deterioration, thromboembolic events, and mortality. 4F-PCC may serve as a viable alternative for reversing FXa inhibitor anticoagulation in intracranial hemorrhage.
Authors
- Stephan A. Mayer (ORCID: https://orcid.org/0000-0002-1272-6277)
- Deepika Dilip (ORCID: https://orcid.org/0000-0002-4961-1481)
- Gular Mammadli
- Nimrod Gozum (ORCID: https://orcid.org/0009-0006-4334-4016)
- Audrey Huang (ORCID: https://orcid.org/0009-0000-5214-1321)
- Jenny Yang (ORCID: https://orcid.org/0009-0007-6276-0530)
- Colleen Bond (ORCID: https://orcid.org/0009-0009-5440-5891)
- Hemangi Rajpal
- William Liu
- Hasit Mehta
- Nicole Davis
- Hannah Young
Institutions
- Westchester Medical Center (US)
- New York Medical College (US)
Publication Details
- Journal
- European journal of medical research
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1186/s40001-026-05399-1
- Primary Topic
- Intracerebral and Subarachnoid Hemorrhage Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Heart Association